Oragenics (LTS:0A64) ROCE % : -445.59% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Oragenics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Oragenics's annualized ROCE % for the quarter that ended in Sep. 2024 was -445.59%.

Oragenics ROCE % Historical Data

The historical data trend for Oragenics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics ROCE % Chart

Oragenics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-80.23

-149.93

-71.14

-71.46

-252.60

Oragenics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-115.72	-1,054.11	-337.51	-466.19	-445.59

Oragenics ROCE % Calculation

Oragenics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-20.625	/	( ( (14.758 - 1.596)	+	(4.966 - 1.798) )	/ 2 )
	=	-20.625	/	( (13.162	+	3.168)	/ 2 )
	=	-20.625	/	8.165
	=	-252.60 %

Oragenics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-9.812	/	( ( (2.71 - 1.383)	+	(5.204 - 2.127) )	/ 2 )
	=	-9.812	/	( ( 1.327	+	3.077 )	/ 2 )
	=	-9.812	/	2.202
	=	-445.59 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Oragenics (LTS:0A64) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Oragenics ROCE % Related Terms

Thank you for viewing the detailed overview of Oragenics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oragenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (LTS:0A64) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

OGEN:USA

Address

1990 Main Street, Suite 750, Tampa, FL, USA, 34236

Website

https://www.oragenics.com

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.

Oragenics Headlines

No Headlines